Zyprexa Relprevv approved for treatment of adult schizophrenia

Share this content:
Zyprexa Relprevv (extended-release olanzapine injectable suspension) has been federally approved for the treatment of schizophrenia in adults. This approval is based on a broad clinical data package involving 2,054 patients, in which Zyprexa Relprevv was found to be effective in controlling symptoms of schizophrenia, including hallucinations, delusions, apathy and social withdrawal.